Elusys initiates third clinical safety study of Anthim, a new anthrax treatment; company successfully completes manufacturing at commercial scale

Media Center PRESS RELEASE 2011 ELUSYS INITIATES THIRD CLINICAL SAFETY STUDY OF ANTHIM, A NEW ANTHRAX TREATMENT; COMPANY SUCCESSFULLY COMPLETES MANUFACTURING AT COMMERCIAL SCALE Elusys CEO to present Anthim program update at Bio Investor Forum, October 26 Pine Brook, NJ – October 24, 2011 – Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company focused on the […]

Elusys awarded $68 million contract to develop Anthim for intramuscular pre- and post-exposure prophylaxis of anthrax infection

Media Center PRESS RELEASE 2011 ELUSYS AWARDED $68 MILLION CONTRACT TO DEVELOP ANTHIM FOR INTRAMUSCULAR PRE- AND POST-EXPOSURE PROPHYLAXIS OF ANTHRAX INFECTION First funding awarded by BARDA (Biomedical Advanced Research & Development Authority) for development of an intramuscular formulation of an anthrax anti-toxin for pre- and post-exposure 
prophylactic use Pine Brook, NJ – September 8, […]

Regulatory Affairs Executive, Greg Torre, PhD, Esq, Joins Elusys Therapeutics Management Team

Media Center PRESS RELEASE 2011 REGULATORY AFFAIRS EXECUTIVE, GREG TORRE, PHD, ESQ, JOINS ELUSYS THERAPEUTICS MANAGEMENT TEAM Pine Brook, NJ – January 11, 2011 – Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, today announced the appointment of Gregory M. Torre, PhD, ESQ, as Vice President of Regulatory and Quality. Dr. Torre brings nearly 30 […]